Clinical Trial Update: Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML [Phase 3]

View source ↗

Summary

Phase 3 trial comparing daunorubicin or idarubicin with cytarabine plus quizartinib versus physician's choice in newly diagnosed FLT3-ITD+ acute myeloid leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Daunorubicin (daunorubicin)
• Idarubicin (idarubicin)
• Quizartinib (Quizartinib)

Snippet

Sponsor: University Hospital Heidelberg | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: WITHDRAWN